Investors and BD Teams
Diligence an asset case you can trace
Whether you are licensing an asset or investing in the company behind it, Pixen supports biotech due diligence with a risk-adjusted value you can take apart line by line, and compare with every other deal on the same method.
What's at stake
"A valuation you can't trace is a valuation you have to discount."
Value any asset on a consistent method.
Probability of success by phase, costs, discounting and two terminal-value methods, with the scenarios you need to test.
See the assumptions, not just the answer.
Every line of the forecast shows its source and the confidence behind it.
Compare deals like for like.
The same structure across every asset you assess, from in-licensing valuation to portfolio review.
- A secure partner view of a company's approved case
FAQ
For Investors and BD Teams
Can we value assets we are evaluating from outside?
Yes. You can build a case for an asset you are assessing, using the same profile, forecast and rNPV structure. We'll confirm the right set-up for your team in the demo.
Can a company share its case with us?
Today companies export their approved case to Excel and PDF. Talk to us about how you would like to review cases with the companies you work with.
How is confidential data protected?
Pixen is hosted on Microsoft Azure and ISO 27001 certified. Each customer works in its own tenant with role-based access. Trust and security →